Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Compare

671 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AUTL Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Autolus

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AUTL Stock 12 Month Forecast

Average Price Target

$8.00

▲(272.09%Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Autolus Therapeutics in the last 3 months. The average price target is $8.00 with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 272.09% change from the last price of $2.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.5323076923076924,3.1546153846153846,3.776923076923077,4.399230769230769,5.021538461538461,5.643846153846154,6.266153846153847,6.888461538461539,7.510769230769231,8.133076923076922,8.755384615384616,9.377692307692309,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.378461538461538,2.8469230769230767,3.315384615384615,3.7838461538461536,4.252307692307692,4.72076923076923,5.189230769230769,5.657692307692307,6.126153846153846,6.594615384615384,7.063076923076923,7.531538461538461,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.91,2.2246153846153844,2.539230769230769,2.853846153846154,3.168461538461538,3.483076923076923,3.7976923076923077,4.112307692307692,4.426923076923077,4.741538461538462,5.056153846153847,5.3707692307692305,5.685384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.68,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.19,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$10.00

Average Price Target$8.00

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$2.5

Hold

16.28%

Upside

Reiterated

06/07/25

The overall score is primarily influenced by financial performance challenges, particularly profitability and cash flow issues. Strong technical momentum and positive earnings call insights slightly offset these concerns, but valuation remains a risk with negative earnings.

Gil BlumNeedham

Needham

$10

Buy

365.12%

Upside

Reiterated

06/12/25

Promising FELIX Study Results for Obe-cel Support Buy Rating Amidst Strong Remission and Survival Rates

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL), Autolus Therapeutics (NASDAQ: AUTL) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Strong Market Entry and Strategic Expansion Drive Buy Rating for Autolus

Yanan ZhuWells Fargo

Wells Fargo

$8→$6

Buy

179.07%

Upside

Reiterated

03/20/25

Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)

Salim SyedMizuho Securities

Mizuho Securities

―

Buy

―

Reiterated

03/20/25

Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects

Rajan SharmaGoldman Sachs

Goldman Sachs

$7.6

Buy

253.49%

Upside

Upgraded

11/18/24

Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated

Simon Baker CFARedburn Atlantic

Redburn Atlantic

$13

Buy

504.65%

Upside

Upgraded

11/15/24

Autolus Therapeutics upgraded to Buy from Neutral at Redburn AtlanticAutolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic

Kelly ShiJefferies

Jefferies

$13

Buy

504.65%

Upside

Reiterated

11/12/24

Jefferies Reaffirms Their Buy Rating on Autolus Therapeutics (AUTL)

James ShinDeutsche Bank

Deutsche Bank

$10

Buy

365.12%

Upside

Reiterated

08/09/24

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$2.5

Hold

16.28%

Upside

Reiterated

06/07/25

Gil BlumNeedham

Needham

$10

Buy

365.12%

Upside

Reiterated

06/12/25

Promising FELIX Study Results for Obe-cel Support Buy Rating Amidst Strong Remission and Survival Rates

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vericel (NASDAQ: VCEL), Autolus Therapeutics (NASDAQ: AUTL) and Pacira Pharmaceuticals (NASDAQ: PCRX)

Matt PhippsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/08/25

Strong Market Entry and Strategic Expansion Drive Buy Rating for Autolus

Yanan ZhuWells Fargo

Wells Fargo

$8→$6

Buy

179.07%

Upside

Reiterated

03/20/25

Wells Fargo Keeps Their Buy Rating on Autolus Therapeutics (AUTL)

Salim SyedMizuho Securities

Mizuho Securities

―

Buy

―

Reiterated

03/20/25

Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects

Rajan SharmaGoldman Sachs

Goldman Sachs

$7.6

Buy

253.49%

Upside

Upgraded

11/18/24

Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated

Simon Baker CFARedburn Atlantic

Redburn Atlantic

$13

Buy

504.65%

Upside

Upgraded

11/15/24

Autolus Therapeutics upgraded to Buy from Neutral at Redburn AtlanticAutolus Therapeutics upgraded to Buy from Neutral at Redburn Atlantic

Kelly ShiJefferies

Jefferies

$13

Buy

504.65%

Upside

Reiterated

11/12/24

Jefferies Reaffirms Their Buy Rating on Autolus Therapeutics (AUTL)

James ShinDeutsche Bank

Deutsche Bank

$10

Buy

365.12%

Upside

Reiterated

08/09/24

Buy Rating Affirmed for Autolus Therapeutics Amid Strong Commercial Prospects and Solid Financials

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Autolus Therapeutics

1 Month

xxx

Success Rate

11/26 ratings generated profit

Average Return

+1.66%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 42.31% of your transactions generating a profit, with an average return of +1.66% per trade.

3 Months

xxx

Success Rate

13/28 ratings generated profit

Average Return

+4.02%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 46.43% of your transactions generating a profit, with an average return of +4.02% per trade.

1 Year

Gil BlumNeedham

Success Rate

11/28 ratings generated profit

Average Return

+3.76%

reiterated a buy rating 2 days ago

Copying Gil Blum's trades and holding each position for 1 Year would result in 39.29% of your transactions generating a profit, with an average return of +3.76% per trade.

2 Years

xxx

Success Rate

11/28 ratings generated profit

Average Return

-4.58%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 39.29% of your transactions generating a profit, with an average return of -4.58% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AUTL Analyst Recommendation Trends

Rating

Jan 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AUTL has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AUTL average Analyst price target in the past 3 months is 8.00.

Each month's total comprises the sum of three months' worth of ratings.

AUTL Financial Forecast

AUTL Earnings Forecast

Next quarter’s earnings estimate for AUTL is -$0.23 with a range of -$0.30 to -$0.19. The previous quarter’s EPS was -$0.26. AUTL beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.02% of the time in the same period. In the last calendar year AUTL has Outperformed its overall industry.

AUTL Sales Forecast

Next quarter’s sales forecast for AUTL is $12.92M with a range of $9.67M to $17.15M. The previous quarter’s sales results were $8.98M. AUTL beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.59% of the time in the same period. In the last calendar year AUTL has Outperformed its overall industry.

AUTL Stock Forecast FAQ

What is AUTL’s average 12-month price target, according to analysts?

Based on analyst ratings, Autolus Therapeutics Plc’s 12-month average price target is 8.00.

What is AUTL’s upside potential, based on the analysts’ average price target?

Autolus Therapeutics Plc has 272.09% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AUTL a Buy, Sell or Hold?

Autolus Therapeutics Plc has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Autolus Therapeutics Plc’s price target?

The average price target for Autolus Therapeutics Plc is 8.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 272.09% Increase from the current price of $2.15.

What do analysts say about Autolus Therapeutics Plc?

Autolus Therapeutics Plc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of AUTL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

AUTL Analyst Ratings

AUTL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Autolus Therapeutics

AUTL Analyst Recommendation Trends

AUTL Financial Forecast

AUTL Earnings Forecast

AUTL Sales Forecast

AUTL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts